BHI issued a Commercial Relevance Award to three companies as part of the Invest Maryland Challenge, Maryland's statewide business plan competition. The three companies each offer a differentiated product or service to the biohealth marketplace with an opportunity to provide significant commercial value to the health industry granting the the Commercial Relevance title..
Sickweather is a Batimore-based health information company that scans social networks for indicators of illness, allowing you to check for the chance of sickness as easily as you can check for the chance of rain.
Care Progress is a Bethesda-based company with a software platform to efficiently manage and treat cancer patients at home and maximize reimbursement through outcomes-based care management.
Tissue Analytics is a Johns Hopkins University spin-out that is transforming the common smartphone into a sophisticated medical imaging system.BHI will offer strategic consulting services with selected companies to support the growth of these businesses and doe do using our knowledge, network and process for assisting early-stage biohealth companies. BHI is pleased to continue to partner with the State of Maryland's Invest Maryland Challenge to support the growth of emerging biohealth businesses.
BioHealth Innovation, Inc. (BHI), a public-private partnership and innovation intermediary is seeking an energetic and motivated life science professional for the role of an Entrepreneur-In-Residence (EIR) with product development experience and subject matter expertise in the fields of neurology and neuroscience. The EIR will reside within the National Institutes of Health (NIH) and will also support intramural and extramural initiatives on an as needed basis.
The EIR program was established at BioHealth Innovation to:
- Retain and bring entrepreneurial talent to the Maryland ecosystem
- Connect resources including institutions, technology assets, people and capital within Maryland that include federal institutions, labs, academic institutions, small businesses, disease foundations and the investor community
- Build/support sustainable life science startups that will add value within the healthcare system and also build upon the existing infrastructure
The EIR will work with BHI leadership to ensure that the activities and outcomes are aligned with BHIs strategic focus.
Congratulations to all the winners in the third InvestMaryland Challenge. All four will receive a $100,000 top prize from the Department of Business and Economic Development. Check out the rest of the prize winners in the list below, and an explanation of all the different prizes provided by sponsors and partners here.
Montgomery College offers Summer 2015 classes designed to meetyour entrepreneurial needs in support of your business ideas.
For Aspiring Entrepreneurs:
The Intentional Entrepreneur:
This one day class helps you identify your entrepreneurial skills and abilities, and addresses any concerns you may have about business ownership. This class is a must for anyone considering starting a business!
Monday, May 18, 2015 6–10 p.m.Saturday, July 11, 2015 9 a.m. – 1 p.m.
For Early Stage Entrepreneurs:
Designed specifically for the entrepreneurs in the early stages of business development.
Wednesdays, June 3–August 5, 2015 6–9 p.m.
For more information, please contact Karen Ambrose, Program Director at 240-567-2592 or e-mail: email@example.com
Don't forget to register NOW for Wednesday's T2 Speakers Series "Commercializing Innovations at Georgetown University" with Georgetown University Office of Technology Commercialization Director Ruchika Nijhara, Ph.D.
Tech Transfer Speakers Series is a free monthly program offered through the Gateway to Innovation: Montgomery Welcome Center for Federal and Academic Tech Transfer. For more information and additional calendar items, please visit TechTransferConnection.com. Engage with others in the tech transfer field by joining the Gateway to Innovation LinkedIn Group. Brought to you by: Montgomery County Department of Economic Development and the Federal Laboratory Consortium for Technology Transfer.
JOIN THE GATEWAY TO INNOVATION LinkedIn Group and start networking with other researchers, federal lab professionals, university technologists, investors, and many others in our area. Move your technology forward by reaching out and connecting!!
University of Maryland (UM) Ventures and Biomecite Diagnostics, LLC announced today the signing of an exclusive option by Biomecite Diagnostics for the rights from University of Maryland, Baltimore (UMB) to develop diagnostics to detect inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Drs. Florian Fricke and James White developed the licensed technology while both were with the University of Maryland School of Medicine's Institute for Genome Sciences (IGS). The technology explores distinctive genomic variances in the populations of bacteria or microbiome found in the human gut to diagnose the closely related but differing gastrointestinal diseases, UC and CD.
Emergent BioSolutions of Gaithersburg has won approval from the U.S. Food and Drug Administration for its hemophilia drug Ixinity.
The treatment, administered intravenously, helps control and prevent bleeding episodes and also is approved for use during surgery in adults and children 12 and older with hemophilia B, according to a company news release. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding.
The Montgomery County Business Hall of Fame will add four new members later this year, including a former space issues attorney turned health company CEO, a bank chairman, a barbecue expert and the chief executive of a hospital.
The following people have been named to the business hall of fame and are scheduled to be honored at an Oct. 27 event:
Photo Credit: Fortune Live Media - Flickr
Drug testing on humans and animals will be a thing of the past within two decades, United Therapeutics CEO Martine Rothblatt said Monday.
Soon, companies will test pharmaceuticals on silicon versions of the human body, entering drugs as code, she said.
Photo Credit: Fortune Live Media - Flickr
Gaithersburg-based molecular diagnostics company OpGen Inc. went public Tuesday, and saw its shares drop more than 20 percent during the day before closing at $4.85, down nearly 19 percent.
CEO Evan Jones said he's not concerned. In the world of biotech, making money can take time.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it has expanded its relationship with BGI, the world's largest genomics organization, to provide QIAGEN's Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI's sequencing services.
Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis' secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation applications. BGI will provide Ingenuity Variant Analysis to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the year. BGI collaborates with more than 10,000 organizations and 30,000 partners worldwide, providing sequencing services for thousands of research projects, including large-scale genome initiatives.
Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis. The FDA has also accepted the company's Investigational New Drug (IND) application to initiate a phase 2 clinical trial of cobiprostone for the prevention of oral mucositis in patients suffering with head and neck cancer receiving concurrent radiation and chemotherapy.
I’ve known Edmund Pendleton from the University of Maryland as the Director of the D.C. National Science Foundation (NSF) I-Corps Node (a collaboration among the University of Maryland, Virginia Tech, George Washington, and Johns Hopkins). But it wasn’t until seeing him lead the first I-Corps class at the National Institutes of Health that I realized Edmund could teach my class better than I can. After seeing the results of 500+ teams through the I-Corps, the NSF now offers all teams who’ve received government funding to start a company an introduction to building a Lean Startup.
UNC and pharmaceuticals giant GlaxoSmithKline are joining forces to try developing a cure for HIV/AIDS, with the British company pledging a five-year, $20 million contribution to the effort.
GSK is also chipping in a 10-person research team, to work with faculty members, post-doctoral fellows and graduate students attached to four different labs in UNC’s medical and pharmacy schools.
Kelly Chu stands at the front of the room and explains a complex spreadsheet displayed on a projector.
With precision she describes the discounted free cash-flow model she built of a food-services and construction company, and walks through its revenue-growth assumptions before making a recommendation on whether or not to invest.
Free, Open Entrepreneur Office Hours for University of Maryland Students, Faculty and Staff, and Regional Entrepreneurs with Bio or Tech-Based Startups or Ideas
Get answers now from experienced entrepreneurs and legal/business professionals on how to build a successful startup company. Receive free and impartial advice, brainstorm business strategies, investigate funding opportunities and learn about the vast resources available to entrepreneurs.
There is nothing like the sight of children to inspire hope, so it was only fitting that University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, began his second annual State of the University Address on May 7 with a performance by the sixth-grade dancers from Southwest Baltimore Charter School.
But there was deeper meaning as well to their presence at his optimistic address “Renew the State. Repair the World” before an overflow crowd at the School of Nursing.
Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.
Your opportunity to submit initial ideas to help the NHLBI Strategic Visioning process will close on May 15. Click on Submit a New Question or Challenge and don’t miss your chance to share your voice!
Since it seems that 1776 can’t go a week without making news, they just announced an Innovation Opportunity Program that they are launching with General Assembly. DC’s Mayor Muriel Bowser along with representatives from TDF Foundation, THEARC, Capital One, MedStar Health, and Microsoft were also on hand for the announcement.
On Tuesday, the Senate Health committee held a hearing on the promise of precision medicine. Last week, the House released draft legislation to support biomedical innovation. And following President Obama's State of the Union in January, the White House unveiled the Precision Medicine Initiative, meant to provide funding to accelerate biomedical research.
What none of these things do directly is to curb the price of speciality drugs—including precision drugs—which cost Americans more than $80 billion in 2013, according to the Campaign for Sustainable Rx Pricing.
The advent of connected devices and M2M is offering a tremendous opportunity for healthcare professionals. Near-ubiquitous mobile networks are allowing carers to diagnose, monitor, and communicate with patients with unprecedented speed and efficacy.
NextGen Angels recently announced plans to bring its brand of under-40, entrepreneur-friendly angel investors to 12 more U.S. cities, with plans for international expansion down the line.
I caught up with CEO Dan Mindus, who founded the group in 2012, about both the expansion and the venture market in the Greater Washington area. Based on our conversation, there are two important things about the local funding market that every entrepreneur should probably know:
Dr. Patrick Soon-Shiong has some big ideas in healthcare, like a vision of a fully connected ecosystem that truly empowers patients to make informed choices about their own care, aided by supercomputers to crunch all the data, including highly complex genomic information. And he’s not afraid to toot his own horn every once in a while.
“We’ve created the Google of genome mapping,” Soon-Shiong, the multibillionaire entrepreneur behind the still-somewhat-mysterious NantHealth and parent company NantWorks, said Monday at the American Telemedicine Association annual meeting in Los Angeles.
Metro areas with strong startup ecosystems depend on success stories and market conditions that converge over time. In the best of circumstances, a regional community can become stronger than the sum of its parts, moving the needle for industries nationally – or even worldwide.
On Wednesday, big names from D.C.'s tech and business circles will come together at DC Inno's State of Innovation event at Artisphere to discuss the area's future for young startups. One of the hot topics for the evening will be exactly how an innovation ecosystem comes together. Tackling the question will be local leaders from Eastern Foundry, Video Blocks, Arlington Economic Development and Springboard Enterprises.
The Biotechnology Industry Organization (BIO), the National Science Foundation (NSF) and the National Institutes of Health (NIH) today announced an agreement to feature Small Business Innovation Research (SBIR) funded early-stage biomedical companies in an expanded Innovation Zone at the 2015 BIO International Convention®. The Innovation Zone companies, focused on drug discovery, diagnostics and other therapeutic platform technologies, will have dedicated exhibit space and participate in BIO One-on-One Partnering™. Select companies will make 15-minute company presentations in the BIO Business Forum. The Innovation Zone will also feature six universities funded under the prestigious NSF Accelerating Innovation Research Program (AIR). This select group will demonstrate advanced biomedical prototypes that are very close to commercialization stage.
Physicians are not only becoming more proficient with EHRs, they are using their systems for more than just reference. That’s the conclusion of a new Accenture survey of more than 2,600 doctors in Australia, Brazil, England, Norway, Singapore and the U.S.
Interoperability is growing as well, albeit slowly. In 2015, for the first time, a majority of U.S. physicians surveyed by Accenture (51 percent) said they “routinely” access patient data from outside their organizations, up just slightly from 45 percent in 2012.
Of all the rumors ever to swirl around the world’s most valuable company, this may be the first that could involve spitting in a plastic cup.
Apple is collaborating with U.S. researchers to help launch apps that would offer some iPhone owners the chance to get their DNA tested, many of them for the first time, according to people familiar with the plans.
When it comes to the Puget Sound region's biotech industry, is it more important to have big anchor companies or an ever-churning ecosystem of small innovators?
That was one of the questions posed to a panel of three biotech executives last week at an industry forum hosted by news website Xconomy at Fred Hutch.
Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV). Based on discussions with the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting, the Company now is planning to submit the Phase 2 trial as one of two pivotal studies for a New Drug Application (NDA) filing in 2016. Simultaneously, the Company announced that the FDA recently designated SYM-1219 as a Qualified Infectious Disease Product (QIDP). SYM-1219 is a novel drug candidate that contains secnidazole, an antibiotic with favorable pharmacokinetics that facilitate administration as a single-dose oral therapy.
Each time 81-year-old Bill Dworsky or his 80-year-old wife Dorothy opens the refrigerator, closes the bathroom door or lifts the lid on a pill container, tiny sensors in their San Francisco home make notes on a digital logbook.
The couple's 53-year-old son, Phil, checks it daily on his smartphone. If there's no activity during a designated time, the younger Dworsky gets an automated email, so he can decide whether to call or stop by. "This is peace of mind, really," he says of the system he installed last year.